Solid-Phase Platform for the Preparation of Dual-receptor Targeted PET Agents

双受体靶向PET药物制备的固相平台

• 批准号: 8567825
• 负责人: Dexing Zeng
• 金额: $ 19.08万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8567825
• 关键词: Affinity; Automation; Avidity; Binding; CXC Chemokines; Cells; Chemistry; Chromatography; Clinical Research; Complex; Development; Discipline of Nuclear Medicine; Disease; Early Diagnosis; Evaluation; Future; Goals; Human; Image; Imaging technology; Label; Ligands; Ligation; Magnetic Resonance Imaging; Malignant neoplasm of pancreas; Metals; Modality; Multimodal Imaging; Nuclear; Optics; Organic Chemistry; Phase; Plant Resins; Positron-Emission Tomography; Preparation; Production; Property; Radioisotopes; Radiolabeled; Reaction; S Phase; Side; Solid; Structure; Testing; Time; Urokinase Plasminogen Activator Receptor; base; chemokine receptor; density; imaging modality; imaging probe; in vivo; interest; novel; novel strategies; pre-clinical; preclinical study; public health relevance; radiotracer; receptor; receptor density; scale up; success

DESCRIPTION (provided by applicant): With the success of receptor-targeted nuclear medicine based agents as well as the influx of new imaging modalities and technologies, there is increasing interest in the development of novel dual-receptor targeted PET agents that have high affinity through multivalency or target two different types of receptors on a single cell. The dual-receptor targeted probes are extremely desirable when both receptors are over-expressed in certain disease but the density of each is relatively low. However, current preparations of such probes require complex organic chemistry, conjugation and radiolabeling strategies, which greatly hinder widespread and routine utilization of promising probes for preclinical and/or clinical studies. Therefore, we are proposing a novel strategy that provides the basis of an efficient, robust and potentially automated platform for the structure optimization and routine production of dual-receptor targeted PET agents for both preclinical and clinical studies. This versatile platform will employ solid-phase synthesis capabilities for preparing PET imaging probes that can target two receptors simultaneously. The solid synthesis platform will significantly facilitate the ease of synthesis by: 1) using a large excess of reactant for fast reactions; 2) increasing the conjugation efficiency via the Staudinger ligation and Cu(I) catalyzed/metal-free click chemistry; 3) radiolabeling and releasing of PET agents from the resins concomitantly; and 4) completely eliminating the need for chromatography purification and significantly increasing specific activity because only radiolabeled agents can be released from the resin and no unlabeled molecule exists in the final PET agent products. By using this platform, dual-receptor targeted PET agents can be obtained in a short time with high specific activity. To validate the synthetic platform, PET agents targeting two low-density receptors that are over-expressed in pancreatic cancer, urokinase plasminogen activator receptor (uPAR) and CXC chemokine receptor 4 (CXCR4), will be prepared and evaluated in cells. In addition, the platform can be easily adapted to prepare multimodal imaging agents for two modalities such as nuclear/optical (or nuclear/magnetic resonance) imaging. If successful, a reliable and robust platform for the rapid preparation of dual-receptor targeted PET agents will be developed. The dual-receptor (uPAR and CXCR4) targeted PET agents will be prepared and evaluated in cells. Combining the advantages offered by dual-receptor targeting strategy and rapid solid-phase platform, the prepared PET agents will provide an excellent opportunity to realize accurate and selective imaging of pancreatic cancer. In a future R01 application, we will develop the automation for scale-up and routine production, perform the structure and reaction conditions optimization, and conduct the comprehensive in vivo evaluation of the dual-receptor targeted PET imaging agents for the early diagnosis of pancreatic cancers.

描述（由申请人提供）：随着受体靶向核医学药物的成功以及新成像模式和技术的涌入，人们对开发新型双受体靶向PET药物的兴趣越来越大，这些药物通过多价性具有高亲和力或靶向单个细胞上的两种不同类型的受体。的 当两种受体在某些疾病中都过表达但每种受体的密度相对较低时，双受体靶向探针是非常理想的。然而，目前这种探针的制备需要复杂的有机化学、缀合和放射性标记策略，这极大地阻碍了有前景的探针在临床前和/或临床研究中的广泛和常规利用。因此，我们提出了一种新的策略，为临床前和临床研究的双受体靶向PET药物的结构优化和常规生产提供了一个高效，稳健和潜在的自动化平台的基础。这个多功能平台将采用固相合成能力来制备可以同时靶向两种受体的PET成像探针。固体合成平台将通过以下方式显著促进合成的容易性：1）使用大量过量的反应物用于快速反应; 2）通过施陶丁格连接和Cu（I）催化的/无金属点击化学增加缀合效率; 3）放射性标记并同时从树脂释放PET试剂;和4）完全消除了对色谱纯化的需要，并且显著增加了比活性，因为只有放射性标记的试剂可以从树脂中释放，并且在树脂中不存在未标记的分子。最终PET剂产品。通过使用该平台，可以在短时间内获得具有高比活性的双受体靶向PET药物。为了验证合成平台，将制备靶向胰腺癌中过表达的两种低密度受体（尿激酶纤溶酶原激活物受体（uPAR）和CXC趋化因子受体4（CXCR 4））的PET试剂，并在细胞中进行评价。此外，该平台可以容易地适用于制备用于两种模态的多模态成像剂，例如核/光学（或核/磁共振）成像。如果成功，将开发一个可靠和强大的平台，用于快速制备双受体靶向PET剂。将制备双受体（uPAR和CXCR 4）靶向PET试剂，并在细胞中进行评价。结合双受体靶向策略和快速固相平台的优势，制备的PET试剂将为实现胰腺癌的精确和选择性成像提供极好的机会。在未来的R 01应用中，我们将开发用于放大和常规生产的自动化，进行结构和反应条件优化，并对用于胰腺癌早期诊断的双受体靶向PET显像剂进行全面的体内评价。